CureVac N.V.

NASDAQ:CVAC

4.07 (USD) • At close January 15, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018
Revenue 53.75867.42102.9948.917.41612.871
Cost of Revenue 124.366183.993238.19514.17327.98317.744
Gross Profit -70.608-116.573-135.20534.727-10.567-4.873
Gross Profit Ratio -1.313-1.729-1.3130.71-0.607-0.379
Reseach & Development Expenses 115.72462.55815.907113.80843.24241.722
General & Administrative Expenses 76.00988.99487.20145.02942.18320.415
Selling & Marketing Expenses 0.4240.4171.7430.7331.7551.085
SG&A 76.43389.41188.94445.76243.93821.5
Other Expenses 11.442-17.682-627.793-0.871.754.729
Operating Expenses 203.599134.279277.058158.788.9367.951
Operating Income -274.207-249.457-412.263-124.002-99.498-72.824
Operating Income Ratio -5.101-3.7-4.003-2.536-5.713-5.658
Total Other Income Expenses Net 14.2380.302-0.235-20.033-0.6271.693
Income Before Tax -259.969-249.155-412.498-129.8-100.125-71.131
Income Before Tax Ratio -4.836-3.696-4.005-2.654-5.749-5.526
Income Tax Expense 0.198-0.126-0.782-0.726-0.2520.11
Net Income -260.167-249.029-411.716-129.074-99.873-71.241
Net Income Ratio -4.84-3.694-3.998-2.64-5.735-5.535
EPS -1.18-1.32-2.21-0.98-0.53-0.4
EPS Diluted -1.18-1.32-2.21-0.98-0.53-0.4
EBITDA -234.09-209.386-386.486-123.095-91.501-69.851
EBITDA Ratio -4.355-3.309-3.753-2.245-5.254-5.211